C4 Therapeutics Inc CCCC shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455.
Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five patients with multiple myeloma. The company said that at the time of the data cut-off, two patients remained on therapy, however, all patients have since discontinued treatment.
Related Link: C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated.
CCCC 52-Week Range: $19.81 - $51.21
According to data from Benzinga Pro, the stock was down 50.8% at $11.27 at time of publication.
Photo: jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
